Myosin in autoinhibited
cardiac reserve
mavacamten
myosin
thick filament
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
medline:
13
2
2024
pubmed:
12
2
2024
entrez:
12
2
2024
Statut:
ppublish
Résumé
Mavacamten is a FDA-approved small-molecule therapeutic designed to regulate cardiac function at the sarcomere level by selectively but reversibly inhibiting the enzymatic activity of myosin. It shifts myosin toward ordered
Identifiants
pubmed: 38346202
doi: 10.1073/pnas.2314914121
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2314914121Subventions
Organisme : NIGMS NIH HHS
ID : P30 GM138395
Pays : United States
Déclaration de conflit d'intérêts
Competing interests statement:C.Z. and R.S. are employees and own shares in Bristol Myers Squibb (formerly MyoKardia). S.G. and S.N. are former employees of Bristol Myers Squibb. C.L.d.R. has a consulting relationship with Bristol Myers Squibb. S.M. and M.P. are partners in FilamenTech, Inc. and they provided the simulations at no cost. W.M. and T.C.I. consults for Edgewise Therapeutics Inc., but this activity has no relation to the current work.